Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Scores and Performance of Patient Reported Outcome Measures in Patients with High Grade Glioma at Diagnosis
Neuro-oncology
P2 - Poster Session 2 (8:00 AM-9:00 AM)
13-005

To report scores of health-related quality of life (HRQOL) surveys and evaluate whether timing of administration influences scores in patients with high-grade glioma (HGG).

Patient reported outcome (PRO) tools are means of reporting HRQOL and alerting clinicians to deficiencies in a patient’s health status. HRQOL in HGG patients may be influenced by many factors. We tested the performance of validated generic (Patient Reported Outcomes Measurement Information System, PROMIS) and disease-specific (Functional Assessment of Cancer Therapy-Brain, FACT-Br) instruments administered soon after diagnosis.

FACT-Br and PROMIS (Depression, Anxiety, Social Roles and Activities, Anger, Cognitive Function, Fatigue, and Global Health [GH]) were administered to adults with HGG after diagnosis at University of Rochester in an IRB-approved study. Regression analysis was used to evaluate the relationship between scores and time of survey administration adjusting for AED-status, seizures, KPS, and tumor treatment.

45 patients (44 grade IV, 1 grade III, median age = 61, range 28-90) completed at least one baseline survey. 42 completed PROMIS domains and 39 completed FACT-BR, a median of 26 days from diagnosis (range 2-90).  Functional impairment reported through PROMIS was similar to that reported in the general population (normalized mean T-score(SD)): Depression (50.8(7.2)), Anxiety (53.0(7.6)), Cognitive (45.9(10.7)), Anger (47.1(6.0)), Social Roles (48.2(8.8)), GH Physical (47.8(7.7)), GH Mental (48.7(8.8)). Adjusting for relevant covariates, there were significant negative linear associations between scores and timing of survey administration for PROMIS anxiety (Beta(SE) = -0.40(0.08)), PROMIS depression (Beta = -0.23(0.10)), and PROMIS anger (Beta = -0.43(0.10)).

Subjects recently diagnosed with HGG reported functional impairment similar to a reference population without cancer. Nonetheless, anxiety, depression, and anger were negatively associated with length of time from tumor diagnosis suggesting these patients may experience higher impairment in these domains that resolves over time.

Authors/Disclosures
Samantha P. Myers, MD
PRESENTER
Ms. Myers has nothing to disclose.
Peggy Auinger (University of Rochester) Ms. Auinger has nothing to disclose.
Gretchen L. Birbeck, MD, MPH, DTMH, FÂé¶¹´«Ã½Ó³»­ (University of Rochester/CHET) An immediate family member of Dr. Birbeck has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various. Dr. Birbeck has a non-compensated relationship as a Ambassador for Zambia with RSTMH that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Joy E. Burke, MD (University of Rochester) No disclosure on file
Chinazom U. Ibegbu, MD (Roswell Park Cancer Institute) Dr. Ibegbu has nothing to disclose.
Nimish A. Mohile, MD, FÂé¶¹´«Ã½Ó³»­ The institution of Dr. Mohile has received research support from Novocure.
Andrea C. Wasilewski, MD (Givens Brain Tumor Center) Dr. Wasilewski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novocure. Dr. Wasilewski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Servier Pharmaceuticals . Dr. Wasilewski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals .
Jennifer N. Serventi, PA (University Of Rochester Medical Center) Ms. Serventi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novocure.
Thomas Wychowski, MD (University of Rochester) The institution of Dr. Wychowski has received research support from UCB.